Better gastrointestinal tolerability with biologics than the conventional therapy

In Switzerland, consenting patients with moderate-to-severe psoriasis enter the SDNTT (Swiss Dermatology Network for Targeted Therapies) Psoriasis Registry when they start systemic treatment. The purpose of adding the outpatient data to the non-interventional registry lies in obtaining long-term evidence for the efficacy and safety of these therapies in psoriasis and comparing adverse and serious adverse events between biological and non-biological drugs. In the evaluation presented, 473 patients were included until December 2016: this corresponds to 264 patient years of biological and 272 years of non-biological systemic therapy [1]. Their mean age was 46.7 years, 65% were male and more than a third not only suffered from psoriasis but also from psoriatic arthritis. Rates of serious adverse events and non-serious infection rates were not significantly different between the two treatment groups. The most reported non-serious adverse events were ineffectiveness of th...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 21 December, 2018